- Home
- NGNE vs MIN Comparison
NGNE vs MIN Comparison
Compare NGNE & MIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- MIN
- Stock Information
- Founded
- NGNE 2003
- MIN 1988
- Country
- NGNE United States
- MIN United States
- Employees
- NGNE N/A
- MIN N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- MIN Trusts Except Educational Religious and Charitable
- Sector
- NGNE Health Care
- MIN Finance
- Exchange
- NGNE Nasdaq
- MIN Nasdaq
- Market Cap
- NGNE 325.3M
- MIN 302.7M
- IPO Year
- NGNE N/A
- MIN N/A
- Fundamental
- Price
- NGNE $18.48
- MIN $2.68
- Analyst Decision
- NGNE Strong Buy
- MIN
- Analyst Count
- NGNE 7
- MIN 0
- Target Price
- NGNE $41.86
- MIN N/A
- AVG Volume (30 Days)
- NGNE 110.1K
- MIN 331.0K
- Earning Date
- NGNE 08-11-2025
- MIN 01-01-0001
- Dividend Yield
- NGNE N/A
- MIN 7.31%
- EPS Growth
- NGNE N/A
- MIN N/A
- EPS
- NGNE N/A
- MIN 0.08
- Revenue
- NGNE N/A
- MIN N/A
- Revenue This Year
- NGNE N/A
- MIN N/A
- Revenue Next Year
- NGNE N/A
- MIN N/A
- P/E Ratio
- NGNE N/A
- MIN $33.38
- Revenue Growth
- NGNE N/A
- MIN N/A
- 52 Week Low
- NGNE $6.88
- MIN $2.52
- 52 Week High
- NGNE $74.49
- MIN $2.88
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- MIN 49.09
- Support Level
- NGNE $19.59
- MIN $2.65
- Resistance Level
- NGNE $20.46
- MIN $2.71
- Average True Range (ATR)
- NGNE 1.23
- MIN 0.03
- MACD
- NGNE -0.20
- MIN -0.00
- Stochastic Oscillator
- NGNE 13.37
- MIN 41.67
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.